Advancing the Understanding of Type 1 Diabetes Pathogenesis (Biosamples Provided from a Primary Prevention Trial)

Written By Diana L Sung

Launched in late 2017, the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) is designed to carry out newborn screening in the general population, identify infants at high genetic risk of developing type 1 diabetes, and offer them participation in trials to prevent disease initiation.

Diana L Sung
Previous

Request for Applications to advance collaborative research in T1D prevention
Next

Breakthrough T1D Request for Applications: Collaborative Advancement of Cures for T1D